Overview

Oral Vinorelbine and Cisplatin and Concurrent Radiotherapy After Induction Chemotherapy in Locally Advanced NSCLC.

Status:
Completed

Trial end date:
2007-06-01

Target enrollment:
0

Participant gender:
All

Summary

Our aim is to conducted a multicenter phase II trial of the cisplatin-oral vinorelbine -radiotherapy combination after induction chemotherapy with cisplatin-docetaxel in patient with NSCLC. Oral vinorelbine will be used in the present study rather than the intravenous form because: 1- Previous investigations have demonstrated that oral vinorelbine is as effective as the intravenous form in the treatment of NSCLC. 2 - We think that the use of oral agents in CT will reduce some disagreements provoked by intravenous injections: stress, infections, hemorrhage, displacement at the hospital and cost of CT. .

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

University Hospital, Brest

Collaborator:

Fabre Clinic

Treatments:

Cisplatin
Vinblastine
Vinorelbine

Criteria

Inclusion Criteria:

histologically or cytologically documented inoperable stage IIIA N2 or IIIB NSCLC
previously untreated, absence of malignant pleural effusion, performance status (PS) =1 and
patient life expectancy of at least 12 weeks.

Exclusion Criteria:

metastatic disease, small Cell lung carcinoma, prior chemotherapy, prior radiotherapy,
resecable tumor, any instable systemic disease, any other malignancies within 5 years,